-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Roy Zwahlen
Roy is a Manager of Intellectual Property and Technology Transfer policy at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his two kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.
Latest Posts
Kirtsaeng v. John Wiley & Sons: No Good Deed Goes Unpunished
The Supreme Court handed Kirtsaeng a victory last week finding his importation and resale of copyrighted books exhausted the copyright under the First Sale Doctrine. In a vain attempt at corporate responsibility, the publishers in this case created two versions of textbooks; a no-frills “Asia edition” to sell at affordable prices to students in less affluent places like Thailand, and a higher quality more expensive version to relatively more affluent students in places like the Read More >
BIO IPCC Conference Launches Next Week
BIO’s IPCC Spring Conference is in San Diego next week, March 25-27. Find this year’s line-up below and follow me on twitter at @rzwahlen for live tweeting of the panels. Pre-Conference Workshop: Effecting and Managing Change Sponsored by: Foley & Lardner LLP The panel will discuss lobbying and public messaging about IP. This workshop will provide an overview and illustrative anecdotes on how to lobby Congress and the administration on certain issues. and how to Read More >
Gene Patents: Common Sense from Down Under
Oh, crikey! The U.S. Supreme Court is currently reviewing briefs to consider whether preparations of DNA molecules are patentable. Possibly unnoticed to the Justices is a recent decision from the Federal Court of Australia confirming the patentability of ‘isolated’ DNA. The Supreme Court may not take any notice of this Australian case, but those following so-called gene patents can learn a lot from the no-nonsense approach of Aussie patent law. The Australian case focuses its Read More >
Parallel Importation: A Disincentive for Developing World Access to Medicines
Parallel importation serves as a challenge to improving access to medicines in the developing world. Parallel importation occurs when a country imports a product from a 3rd country to take advantage of a cheaper price than what is present for the same product in-country. The imports then directly and unfairly competes with the same product sold by the rights holder on the local market. Unfortunately for those most in need of special access to medicine Read More >
Brazil Patent Policy: At a Crossroads
The Government of Brazil approaches the patent policy crossroads with two ministries wanting to move in opposite directions. In the last few months, both the Brazilian Patent Office (INPI) and the Brazilian Regulatory Authority (ANVISA) issued proposed rules concerning patents and are sifting through public comments to determine how they will deal with biotech patents. A quirk in Brazilian law requires that the health regulatory authority (ANVISA) must provide “prior consent” on the grant of a pharmaceutical patent. Traditionally, Read More >
